Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JULIAN J JAVIER

Allopathic & Osteopathic Physicians Internal Medicine Interventional Cardiology

NPI
1013938331
CMS profile
46222
Location
NAPLES, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$16,412.34

42 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Long term medical supply or device loan $15,000.00 1
Food and Beverage $1,412.34 41

By paying entity

PY2022 · entire year · sorted by reported total

Page 1 of 1; records 1–42 of 42 matching records. This page contains 42 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JULIAN J JAVIER

NPI 1013938331 · CMS profile ID 46222

Allopathic & Osteopathic Physicians / Internal Medicine / Interventional Cardiology

NAPLES, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–42 of 42 matching records. This page contains 42 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1013938331?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JULIAN J JAVIER, NPI 1013938331, CMS profile ID 46222. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–42 of 42 matching records. This page contains 42 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1013938331?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). JULIAN J JAVIER, NPI 1013938331, CMS profile ID 46222. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–42 of 42 matching records. This page contains 42 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1013938331?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
JULIAN J JAVIER, NPI 1013938331, CMS profile ID 46222, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–42 of 42 matching records. This page contains 42 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1013938331?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

42 matching records · $16,412.34 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 42 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–42 of 42.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $13.5812/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949530335 CMS
PFIZER INC. $14.4712/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949461861 CMS
Novartis Pharmaceuticals Corporation $33.6812/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893787053 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $16.0412/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887662801 CMS
Amgen Inc. $12.0811/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939466063 CMS
Janssen Pharmaceuticals, Inc $17.9711/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885973113 CMS
Amgen Inc. $19.0611/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939466061 CMS
Novartis Pharmaceuticals Corporation $166.2411/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893787049 CMS
Novartis Pharmaceuticals Corporation $102.2511/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893787045 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $12.7611/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887662803 CMS
Chiesi USA, Inc. $19.8110/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 960798633 CMS
Novartis Pharmaceuticals Corporation $22.3210/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893787255 CMS
Boston Scientific Corporation $28.2210/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 916635679 CMS
Janssen Pharmaceuticals, Inc $15.4309/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885973121 CMS
Philips Electronics North America Corporation $19.5409/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945615883 CMS
Bayer HealthCare Pharmaceuticals Inc. $28.6508/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930322115 CMS
AstraZeneca Pharmaceuticals LP $12.2308/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920251755 CMS
Amgen Inc. $22.1408/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939466059 CMS
Novartis Pharmaceuticals Corporation $22.8208/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893787251 CMS
Alnylam Pharmaceuticals Inc. $25.0007/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 926078975 CMS
Novartis Pharmaceuticals Corporation $23.5707/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893787247 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $13.5707/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887662805 CMS
Janssen Pharmaceuticals, Inc $16.7206/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885973127 CMS
AngioDynamics, Inc. $15,000.0005/31/2022 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 906327419 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $23.4905/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887662807 CMS
Novartis Pharmaceuticals Corporation $21.4405/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893787243 CMS
Inari Medical, Inc. $296.0605/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959274241 CMS
PFIZER INC. $17.7605/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949135601 CMS
Bayer HealthCare Pharmaceuticals Inc. $21.5005/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930033893 CMS
PFIZER INC. $13.1404/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949112381 CMS
AtriCure, Inc. $29.3104/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932210813 CMS
Novartis Pharmaceuticals Corporation $9.5204/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893787235 CMS
Novartis Pharmaceuticals Corporation $19.4504/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893787239 CMS
Novartis Pharmaceuticals Corporation $18.6803/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893787041 CMS
Janssen Pharmaceuticals, Inc $14.3303/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885973107 CMS
Biosense Webster, Inc. $123.3503/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887038045 CMS
Bard Peripheral Vascular, Inc. $21.4302/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 936033757 CMS
Inari Medical, Inc. $17.3602/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959274237 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $21.4702/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887662809 CMS
Inari Medical, Inc. $20.8402/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959274233 CMS
Bayer HealthCare Pharmaceuticals Inc. $21.8702/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929956999 CMS
Novartis Pharmaceuticals Corporation $23.1901/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893787231 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $324.33 8
PY2020 $647.84 12
PY2021 $6,299.17 17
PY2022 $16,412.34 42
PY2023 $811.37 35
PY2024 $4,015.54 62
PY2025 $257.57 14

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $756,135.24 21
PY2024 Recipient $8,192.73 2
PY2024 Principal investigator $381,084.38 10
PY2023 Principal investigator $42,942.49 5
PY2022 Principal investigator $69,643.14 4
PY2021 Principal investigator $89,438.04 5
PY2020 Principal investigator $148,803.32 9
PY2019 Principal investigator $208,129.74 16

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

21 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $31,277.55 12/31/2025 Non-covered Recipient Entity
Advanced Research for Health Improvement, LLC
A Phase 3 International, Multicenter, Open-label Study to Evaluate the Safety and Immunogenicity of 9vHPV Vaccine Administered as 2-dose Regimen with Extended Dosing Intervals in 9- to 14-Year Old Boys and Girls Compared with a Standard 3-dose Regimen in No dispute reported 06/30/2026 1232937970
Principal investigator 1 Eli Lilly and Company $19,500.00 12/22/2025 Non-covered Recipient Entity
ADVANCED RESEARCH FOR HEALTH IMPROVEMENT LLC
A STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WITH PERIPHERAL ARTERY DISEASE: A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL. No dispute reported 06/30/2026 1187874137
Principal investigator 1 Merck Sharp & Dohme LLC $83,252.98 12/15/2025 Non-covered Recipient Entity
Advanced Research for Health Improvement, LLC
A Phase 3 International, Multicenter, Open-label Study to Evaluate the Safety and Immunogenicity of 9vHPV Vaccine Administered as 2-dose Regimen with Extended Dosing Intervals in 9- to 14-Year Old Boys and Girls Compared with a Standard 3-dose Regimen in No dispute reported 06/30/2026 1232937924
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
ADVNCD RSRCH FOR HLTH IMPRVMT
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220626877
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
ADVNCD RSRCH FOR HLTH IMPRVMT
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220626875
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $6,676.96 10/29/2025 Non-covered Recipient Entity
ADVNCD RSRCH FOR HLTH IMPRVMT
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220994257
Principal investigator 1 Novartis Pharmaceuticals Corporation $19,300.00 10/23/2025 Non-covered Recipient Entity
ADVANCED RESEARCH FOR HEALTH IMPROVEMENT LLC
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190308796
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
ADVNCD RSRCH FOR HLTH IMPRVMT
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220626873
Principal investigator 1 AstraZeneca Pharmaceuticals LP $30,423.20 09/24/2025 Non-covered Recipient Entity
ADVANCED RESEARCH FOR HEALTH IMPROVMENT LLC
A Multicentre, Parallel-group, Phase IIb, Randomised, Double blind, Placebo-controlled, 4-Arm, 24-Week Study to Evaluate the Efficacy and Safety of AZD6793 Tablets in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PRESTO) No dispute reported 06/30/2026 1185549913
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $21,200.00 09/22/2025 Non-covered Recipient Entity
Advanced Research for Health Improvement, LLC
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220815153
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 09/01/2025 Non-covered Recipient Entity
ADVNCD RSRCH FOR HLTH IMPRVMT
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220626865
Principal investigator 1 Boehringer Ingelheim International GmbH $23.75 09/01/2025 Non-covered Recipient Entity
ADVNCD RSRCH FOR HLTH IMPRVMT
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220626867
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 09/01/2025 Non-covered Recipient Entity
ADVNCD RSRCH FOR HLTH IMPRVMT
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220626869
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
ADVNCD RSRCH FOR HLTH IMPRVMT
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220626871
Principal investigator 1 Amgen Inc. $5,308.00 03/25/2025 Non-covered Recipient Entity
ADVANCED RESEARCH FOR HEALTH IMPROVEMENT, LLC
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a) No dispute reported 06/30/2026 1246638869
Principal investigator 1 Eli Lilly and Company $6,097.21 01/27/2025 Non-covered Recipient Entity
MILLENNIUM PHYSICIAN GROUP
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187885332
Principal investigator 1 Novartis Pharmaceuticals Corporation $19,917.53 01/17/2025 Non-covered Recipient Entity
ADVANCED RESEARCH FOR HEALTH IMPROVEMENT LLC
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190308794
Principal investigator 1 Amgen Inc. $56,473.43 01/16/2025 Non-covered Recipient Entity
ADVANCED RESEARCH FOR HEALTH IMPROVEMENT LLC
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a) No dispute reported 06/30/2026 1246638867
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,198.67 01/15/2025 Non-covered Recipient Entity
ADVANCED RESEARCH FOR HEALTH IMPROVEMENT
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190310158
Principal investigator 1 AstraZeneca Pharmaceuticals LP $58,812.25 01/08/2025 Non-covered Recipient Entity
ADVANCED RESEARCH FOR HEALTH IMPROVMENT LLC
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS No dispute reported 06/30/2026 1185549911
Principal investigator 1 Eli Lilly and Company $395,372.77 01/07/2025 Non-covered Recipient Entity
ADVANCED RESEARCH FOR HEALTH IMPROVEMENT LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187875251